Abstract
The American Society of Clinical Oncology recommends that full weight-based doses of chemotherapy be used to treat obese patients with cancer. However, many oncologists limit the dose of chemotherapy based on ideal body weight or a maximum body surface area (BSA) of m2. The objective of our study is to determine how weight-based chemotherapy dosing affects toxicity, treatment delays, and laboratory values in a cohort of obese gynecologic cancer patients at our institution. We hypothesize that full weight-based dosing in obese patients does not increase adverse chemotherapy outcomes.
Keywords: chemotherapy, obesity, dosage
How to Cite:
Hansen, J., Stephan, J., Freesmeier, M., Bender, D. P., De Geest, K., Button, A. & Goodheart, M. J., (2013) “The effect of weight-based chemotherapy dosing in a cohort of gynecologic oncology patients”, Proceedings in Obstetrics and Gynecology archive 3(3), 1–2. doi: https://doi.org/10.17077/2154-4751.1235
Rights: Copyright © Jean Hansen, Jean-Marie Stephan, Michelle Freesmeier, David P. Bender, Koen De Geest, Anna Button, Michael J. Goodheart, 2013
Downloads:
Download pdf
View PDF
592 Views
337 Downloads